soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction of and tirzepatide for patients with type 2 diabetes in clinical practice The SOUL trial (Semaglutide Cardiovascular

Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade Kokura, Yoji, et al., Science Direct (2024)

This medication works by supplementing or replacing the body's natural thyroid hormone, thereby restoring normal metabolic function

Tirzepatide lowers blood sugar, and if you are also taking insulin or a sulfonylurea alongside it, your blood sugar can drop too low (hypoglycemia)

At 265 lb, exposure ran 25% to 30% lower. On that class-based model, 1 mg in a 155 lb person can approximate the exposure produced by 1.5 mg in the 240 lb trial cohort

difficile -associated disease (CDAD)

Dallas isnt considering reducing coverage for employees who use the medications to treat Type 2 diabetes, calling them proven, standard treatments that can reduce the risk of heart attacks, strokes and kidney disease, the citys human resources department said in a written statement The more complex question is weight management coverage for employees without a diabetes diagnosis, city officials said